Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma By Ogkologos - June 18, 2025 726 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Breast Cancer Survivor Earned Yoga Instructor Certification During Chemo. Now She... May 8, 2019 Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer March 11, 2019 GPRC5D Is An Active Immunotherapeutic Target in Multiple Myeloma October 5, 2022 FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC September 18, 2024 Load more HOT NEWS Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis... Brentuximab May Mean Less Radiation for Children, Teens with Hodgkin Lymphoma Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo... Corgi Named Dolly Didn’t Win At Westminster, But Is A Champion...
